Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study will look at whether adding daily oral zinc supplements to targeted therapy plus immunotherapy may help people with unresectable or advanced hepatocellular carcinoma, a common type of liver cancer. About 60 participants will take part in this study. Participants will be randomly assigned to one of three groups. One group will receive targeted therapy plus immunotherapy without extra zinc. The other two groups will receive the same type of cancer treatment together with either 20 mg or 30 mg of elemental zinc each day. The main goal is to compare how many participants have their tumors shrink or disappear by Week 18. Researchers will also look at tumor response at earlier time points, how long the cancer remains under control, overall survival, and treatment safety. Blood tests will be used to measure zinc and copper levels during the study. Researchers will also study changes in immune cells, including T cells, to better understand whether zinc supplementation may affect the body's immune response to cancer treatment. This study is designed to explore whether oral zinc supplementation is safe and may improve the effects of targeted therapy plus immunotherapy. The results may help determine which zinc dose should be studied in larger clinical trials.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-75 lat, możliwość zrozumienia badania i wyrażenia pisemnej zgody
- •Potwierdzony rozpoznaniem rak wątroby, który nie można operować, nawrócił się lub dał przerzuty
- •Spodziewana długość życia ponad 3 miesiące
- •Dobry ogólny stan zdrowia (możliwość normalnego funkcjonowania w codziennych czynnościach)
- •Co najmniej jeden mierzalny guz bez wcześniejszego leczenia lokalnego
- •Dobna funkcja wątroby bez poważnych powikłań
- •Stan zaawansowania guza odpowiedni do tego badania
- •Pacjent nigdy nie otrzymywał poprzedniego ogólnoustrojowego leczenia tego nowotworu
✗ Disqualifies
- •Wcześniejsze systemic (ogólnoustrojowe) leczenie przeciwnowotworowe, w tym immunoterapia lub terapia celowana
- •Wcześniejsze lokalne leczenie guza (operacja, ablacja, chemioterapia wstrzykiwana w tętnicę)
- •Zmiana zaplanowanego leczenia w trakcie badania
- •Jeśli leczenie zawiera określony lek, badacz może wymagać endoskopii przełyku do sprawdzenia żylaków
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- September 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
Hefei, China
Trial contact
Yao Liu, Dr
Hua Lu, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.